 |
- Available now on PlayStation®4, PlayStation®5, and Nintendo Switchâ„¢, with updated language support on Steam®.
- Digital versions are available for immediate download and play through the PlayStation Store and Nintendo eShop.
SEOUL, South Korea, Nov. 28, 2024 /PRNewswire/ -- Gravity, a global leader in gaming, officially launched Tokyo Psychodemic on November 28 in global markets, excluding Japan.
Tokyo Psychodemic delivers a 2D cinematic forensic investigation experience, immersing players in a post-pandemic world confronting supernatural phenomena. The game involves investigating unsolved cases using forensic expertise and teamwork, with multiple endings determined by the chosen methods for solving cases.
Gameplay consists of two main segments: scenario exploration and evidence collection. Scenario exploration provides detailed case narratives and psychological depth for characters, brought to life through live 2D animations and dynamic still images. Evidence collection focuses on analyzing crime scene data - including photos, videos, audio recordings, and text files - to uncover clues. Collaborative discoveries advance the story, creating an engaging investigative dynamic.
Live-action CCTV footage and an interactive evidence board enhance immersion, delivering a realistic investigative experience.
Gravity launched Tokyo Psychodemic for PlayStation®4, PlayStation®5, and Nintendo Switchâ„¢ in global markets excluding Japan. Digital versions are available for immediate purchase and play through the PlayStation Store and Nintendo eShop. Language options include Korean, English, Japanese, Simplified Chinese, and Traditional Chinese. Updated language support is available on Steam®. The Japanese-only version of Tokyo Psychodemic was initially released in May on PlayStation®4, PlayStation®5, and Nintendo Switchâ„¢ exclusively for Japan.
Yoo Joon, Head of Gravity's Console Publishing Business Team, stated, "Tokyo Psychodemic combines 2D graphics with live-action visuals and multidimensional characters, offering an engaging mystery drama experience. The game delivers the core thrill of deduction-based gameplay alongside cinematic storytelling, to bring fascination to fans of mystery and adventure."
Detailed information about playing Tokyo Psychodemic on Steam®, PlayStation®4, PlayStation®5, and Nintendo Switchâ„¢ is available on the official pages for each platform.
[Gravity Official Website] http://www.gravity.co.kr
[Gravity PC & Console Information Page] https://www.startwithgravity.net/
[Tokyo Psychodemic Official Website] https://tokyo-psychodemic.com/?lang=en
[Tokyo Psychodemic Official Steam Page] https://store.steampowered.com/app/2397140/____XFILE/
[Tokyo Psychodemic Official PlayStation Store Page] https://store.playstation.com/en-us/concept/10008939
[Tokyo Psychodemic Official Nintendo Switch Page] https://www.nintendo.com/us/store/products/tokyo-psychodemic-switch/
Contacts
Gravity Co., Ltd.
Alex Won, Gravity 2Business Unit
alexw@gravity.co.kr
- Available now on PlayStation®4, PlayStation®5, and Nintendo Switchâ„¢, with updated language support on Steam®.
- Digital versions are available for immediate download and play through the PlayStation Store and Nintendo eShop.
SEOUL, South Korea, Nov. 28, 2024 /PRNewswire/ -- Gravity, a global leader in gaming, officially launched Tokyo Psychodemic on November 28 in global markets, excluding Japan.
Tokyo Psychodemic delivers a 2D cinematic forensic investigation experience, immersing players in a post-pandemic world confronting supernatural phenomena. The game involves investigating unsolved cases using forensic expertise and teamwork, with multiple endings determined by the chosen methods for solving cases.
Gameplay consists of two main segments: scenario exploration and evidence collection. Scenario exploration provides detailed case narratives and psychological depth for characters, brought to life through live 2D animations and dynamic still images. Evidence collection focuses on analyzing crime scene data - including photos, videos, audio recordings, and text files - to uncover clues. Collaborative discoveries advance the story, creating an engaging investigative dynamic.
Live-action CCTV footage and an interactive evidence board enhance immersion, delivering a realistic investigative experience.
Gravity launched Tokyo Psychodemic for PlayStation®4, PlayStation®5, and Nintendo Switchâ„¢ in global markets excluding Japan. Digital versions are available for immediate purchase and play through the PlayStation Store and Nintendo eShop. Language options include Korean, English, Japanese, Simplified Chinese, and Traditional Chinese. Updated language support is available on Steam®. The Japanese-only version of Tokyo Psychodemic was initially released in May on PlayStation®4, PlayStation®5, and Nintendo Switchâ„¢ exclusively for Japan.
Yoo Joon, Head of Gravity's Console Publishing Business Team, stated, "Tokyo Psychodemic combines 2D graphics with live-action visuals and multidimensional characters, offering an engaging mystery drama experience. The game delivers the core thrill of deduction-based gameplay alongside cinematic storytelling, to bring fascination to fans of mystery and adventure."
Detailed information about playing Tokyo Psychodemic on Steam®, PlayStation®4, PlayStation®5, and Nintendo Switchâ„¢ is available on the official pages for each platform.
[Gravity Official Website] http://www.gravity.co.kr
[Gravity PC & Console Information Page] https://www.startwithgravity.net/
[Tokyo Psychodemic Official Website] https://tokyo-psychodemic.com/?lang=en
[Tokyo Psychodemic Official Steam Page] https://store.steampowered.com/app/2397140/____XFILE/
[Tokyo Psychodemic Official PlayStation Store Page] https://store.playstation.com/en-us/concept/10008939
[Tokyo Psychodemic Official Nintendo Switch Page] https://www.nintendo.com/us/store/products/tokyo-psychodemic-switch/
Contacts
Gravity Co., Ltd.
Alex Won, Gravity 2Business Unit
alexw@gravity.co.kr
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Gravity Announces Global Release of Tokyo Psychodemic
FREMONT, Calif., Jan. 13, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, is proud to announce the launch of its Research Use Only (RUO) NULISAqpcr™ AD 5-plex Assay. This innovative solution enables simultaneous quantitative measurement of five critical blood-based biomarkers relevant to the Alzheimer's Association recommended guidelines: brain-derived phosphorylated tau 217 (BD-pTau217), neurofilament light chain (NfL), amyloid-beta 42 (Aβ42), glial fibrillary acidic protein (GFAP), and APOE4 (carrier status), all from a single blood or plasma sample.
The NULISAqpcr AD 5-plex Assay consolidates key biomarkers into a single multiplexed format, delivering unmatched sensitivity, specificity, and ease of use. By incorporating BD-pTau217, Aβ42, NfL, and GFAP, the assay enables robust monitoring of amyloid and tau pathology, neurodegeneration, and inflammation, while accurately determining APOE4 carrier status—the strongest genetic risk factor for Alzheimer's disease. Together, these capabilities create a powerful tool for both translational and clinical research, and its relevance extends beyond Alzheimer's disease to other neurodegenerative and cognitive disorders.
"The launch of the NULISAqpcr AD 5-plex Assay marks a significant milestone in our efforts to deliver precision proteomics solutions for neurodegenerative disease," said Dr. Yuling Luo, founder, chairman and chief executive officer of Alamar. "By combining these critical protein targets into a single assay with a streamlined workflow, we are empowering the neuroscience community to advance screening, early detection and precision diagnoses for Alzheimer's disease."
"Blood-based biomarkers are redefining Alzheimer's research, providing an accurate, cheaper and more accessible means of establishing early diagnosis and aiding determination of eligibility for therapies," said Dr. Steven Williams, chief scientific officer of Alamar. "Traditional single-plex assays can measure these biomarkers individually, but require multiple tests to provide a comprehensive view of the disease. With NULISA™ it is now possible to measure multiple Alzheimer's-related proteins in blood, each offering unique insights into the underlying pathophysiology."
Alamar is dedicated to collaborating with researchers, clinicians, and industry partners to unlock precision proteomics and improve outcomes for patients affected by Alzheimer's disease and other neurodegenerative conditions. The NULISAqpcr AD 5-plex Assay is available today as a service through our Technology Access Program.
For more information about the NULISAqpcr AD 5-plex Assay and Alamar's full portfolio of precision proteomic solutions, visit www.alamarbio.com.
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer's Disease Research
Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer's Disease Research
